REG - Belluscura PLC - Appointment of Allenby Capital as Joint Broker

BelluscuraAnnouncement

20/12/2024 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241220:nRST9957Qa&default-theme=true

RNS Number : 9957Q  Belluscura PLC  20 December 2024

20 December 2024

 

BELLUSCURA PLC

("Belluscura" or the "Company")

 

Appointment of Allenby Capital as Joint Broker

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology, is pleased to announce
the appointment of Allenby Capital Limited as the Company's Joint Broker with
immediate effect.

 

For further information please contact:

 

 Belluscura plc                                              Tel: +44 (0)20 3128 8100
 Adam Reynolds, Chairman

 Robert Rauker, CEO

 Simon Neicheril, Chief Financial Officer

 SPARK Advisory Partners Limited                             Tel: +44 (0)20 3368 3550

 Nominated Adviser
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited                                     Tel: +44 (0)20 3903 7715

 Joint Broker
 James Serjeant / Colin Clime (Sales and Corporate Broking)

 Russell Cook / Nicholas Chambers (Corporate Finance)

 Allenby Capital Ltd                                         Tel: +44 (0)20 3328 5656

 Joint Broker
 Guy McDougall / Amrit Nahal (Sales and Corporate Broking)

 Jeremy Porter / Lauren Wright (Corporate Finance)

 MHP                                                         Tel: +44 (0)20 3128 8100

 Financial PR & Investor Relations                           email: Belluscura@mhpgroup.com (about:blank)
 Katie Hunt/Matthew Taylor

 

About Belluscura plc (https://ir.belluscura.com/)

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPTMBATMTBTBPI